InvestorsHub Logo
Followers 23
Posts 2120
Boards Moderated 0
Alias Born 06/21/2015

Re: None

Tuesday, 12/29/2015 3:08:06 PM

Tuesday, December 29, 2015 3:08:06 PM

Post# of 462519
Worth reading again...

Upcoming Milestones:

-PART B data updates for 12, 26, 38, 52 week timeframes of the ongoing Phase 2a Alzheimer’s trial for ANAVEX 2-73.
-Report pharmacokinetics and pharmacodynamics (PK/PD) data for PART A of the Phase 2a trial.
-Initiate double-blinded, randomized, placebo-controlled Phase 2 human trial of ANAVEX 2-73 in non-disclosed indication.
-In addition to ongoing Phase 2a trial currently in PART B, start larger, double-blinded, randomized, placebo-controlled Phase 2/3 trial of ANAVEX 2-73 for Alzheimer’s disease.
-Advance preclinical research with ANAVEX pipeline compounds in neurodegenerative diseases, pain and various types of cancer – ongoing.
-In-licensing to complement current pipeline – ongoing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News